Merck KGaA sees higher profits on cost cutting; Daiichi chair steps down amid Ranbaxy sale;

@FiercePharma: GlaxoSmithKline exec blindsided by Chinese bribery charges: Reuters. Report | Follow @FiercePharma

@TracyStaton: Words, words, and overheated words fly as U.K. officials keep grilling Pfizer. ICYMI yesterday | Follow @TracyStaton

@EricPFierce: Canada orders Biolyse to halt production of injectable drug paclitaxel at a plant in Ontario.More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI: This week's issue of FiercePharmaMarketing: Report | Follow @CarlyHFierce

> Germany-based Merck KGaA said cost cuts help offset negative currency effects in its first-quarter results, which included a slight rise in earnings to 807 million euros, or about $1.11 billion. Report

> The chairman of Japanese drugmaker Daiichi Sankyo, Takashi Shoda, is stepping down as the company offloads the troubled Indian generics company Ranbaxy Laboratories, whose acquisition he engineered. Report

> India's Wockhardt recalled 109,000 bottles of its generic version of the heart pill Toprol XL in the U.S., after the pills failed dissolution tests. Report

> Reckitt Benckiser signed on to develop and sell XenoPort's drug to treat alcoholism, with a $20 million up front payment and up to $120 million in milestones. Report

> Slovenia's Krka posted a 17% drop in first-quarter profits to €42.5 million, blaming the results on negative currency effects that took a €14 million bite out of earnings. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: J&J's new incubator opens its arms to med tech startups. Article | Follow @FierceMedDev

@VarunSaxena2: Interesting FDA meeting summary. "The following questions were discussed:" [copy Qs from preview] [paste]. More | Follow @VarunSaxena2

@MichaelGFierce: Boston College team makes zinc nano-cages for 'smart' cancer drug delivery. ICYMI from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Stabilizing spoon counteracts tremors, helps Parkinson's patients eat. More from NPR | Follow @EmilyWFierce

> Boston Scientific to buy Bayer's device unit for $415 million. More

> Refuse to Accept policy not leading to faster approvals. Story

> Purdue engineering students develop device to test pacemaker lead attachment. Article

Biotech News

@FierceBiotech: AstraZeneca: Coming up from behind--fast--with top cancer programs. Story | Follow @FierceBiotech

@JohnCFierce: ZS Pharma looks to $86M IPO to fund PhIII hyperkalemia studies. News | Follow @JohnCFierce

@DamianFierce: NY Times "the only newsroom in the country that is actually better than it was a generation ago," reports NY TimesMore | Follow @DamianFierce

@EmilyMFierce: Investigational treatment may provide relief for asthma. More from FierceBiotechResearch | Follow @EmilyMFierce

> Novartis-backed Sorbent grabs first tranche in $15M heart therapy round. More

> Bristol-Myers Squibb: It's all about the 'breakthrough' drug nivolumab now. Report

> Bluebird bio buoyed by news of looming trial data. Item

Pharma Manufacturing News

> The man behind Daiichi Sankyo buyout of Ranbaxy gives up chairman's role. More

> Daiichi Sankyo turns over domestic logistics to Yasuda Warehouse. Report

> Hospira says it can prevent shortage after Canada closes Biolyse plant. Article

> Wockhardt recalling 110,000 bottles of generic Toprol XL. More

> Couple who ran wholesaling scam plead guilty. News

Vaccines News

> Mayo Clinic: Massive dose of measles vax killed cancer. Item

> Computer model can boost child vaccination rates while cutting costs. More

> MERS an 'emerging market opportunity,' Novavax CFO says. Report

> People most in need of Merck's shingles jab often not vaccinated. Story

> Sanofi steps up meningitis marketing amid lagging Menactra sales. Article

And Finally... Honey bees crucial to crop pollination are still dying off at a significant rate, a new report states. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.